Other important driver mutations such as anaplastic lymphoma kinase (ALK) rearrangement has a reported prevalence of 2- 7 % [6] and rearrangements of the ROS1 gene occurring in 1–2 % of non-small cell lung cancers (NSCLCs) [7] . This evidence concerns the gene ALK and non-small cell lung carcinoma.